Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Device Drops Blood Pressure in Patients With Difficult-to-Treat Hypertension

06.04.2011
A device designed to treat people with resistant hypertension helped lower blood pressure by 33 points, a substantial drop that would otherwise require patients to take an additional three or four drugs, on top of this subgroup’s usual regimen of up to five drugs, to control their difficult-to-treat condition.

The device, called the Rheos® System, was tested in a pivotal Phase III study presented today as a late-breaking clinical trial at the American College of Cardiology’s Annual Scientific Sessions. It is the first device to be tested in a large-scale clinical trial for the treatment of hypertension and works by activating the body’s natural blood flow regulation mechanism to reduce high blood pressure.

Though the therapy led to a considerable drop in blood pressure and had a good safety profile, it did not meet all of the study goals. Another, more focused trial testing the device is needed before the U.S. Food and Drug Administration will consider approving the treatment, according to physicians who led the study.

“The device works extremely well and there is a large group of patients who would benefit from this therapy, but we need to go back and identify this group more clearly,” said John Bisognano, M.D., Ph.D., a lead study investigator from the University of Rochester Medical Center. “This outcome is not uncommon. While the initial results are not as crisp as we would expect, it is clear from looking at the data that there are therapeutic benefits to pursue.”

The pivotal trial included 265 patients with resistant hypertension treated at 40 medical centers in the United States and two in Europe, and is the latest in a series of studies that have shown the device is beneficial.

People who do not respond to the typical treatment regimen for high blood pressure, which includes one to three medications, coupled with improved nutrition and exercise, have resistant hypertension. These patients are at a far greater risk for stroke, heart attack, heart failure, kidney disease and death, which is why new therapies like Rheos are needed.

“Current drugs and lifestyle modifications can only do so much. I treat a huge number of people who are doing everything right – taking their medications, maintaining a healthy diet, working out – and they still develop resistant hypertension,” noted Bisognano, Professor of Medicine and Director of Outpatient Cardiology at the Medical Center.

The prevalence of resistant hypertension is unknown, but current estimates suggest that between 10 and 15 percent of people with high blood pressure are in the truly resistant group. Many people with a family history of high blood pressure have the condition. Older age is also associated with the disorder.

The Rheos System, developed by CVRx Inc. of Minneapolis, regulates blood pressure much like a pacemaker regulates heart rhythm. A battery-powered implantable generator is inserted under the skin near the collarbone and two leads, or wires, run from the generator to the carotid arteries, the two main arteries that supply blood to the head. The device triggers specific receptors on these arteries, known as carotid baroreceptors – key regulators of blood flow in the body.

These receptors then send signals that are interpreted by the brain as a rise in blood pressure. The body responds to this phantom rise in blood pressure by taking action to lower it, including relaxing the blood vessels and reducing the heart rate.

Rheos was first implanted in the United States in 2005 by physicians at the University of Rochester Medical Center. According to Bisognano, the next trial will include a different selection of patients and use a slightly different implantation technique. He believes the study will likely show that the device, in combination with drug therapy and lifestyle changes, provides major benefit for people with resistant hypertension.

In a separate sub-analysis from the pivotal Phase III study, researchers found that the Rheos device also leads to positive changes in the structure and function of the heart. Years of high blood pressure can damage the heart, resulting in the thickening and enlargement of the heart. Rheos reversed this damage in patients, improving the overall pumping action of the heart – an outcome that doesn’t always result from drug therapy.

“The device lowers blood pressure in a way that actually benefits patients beyond changing their numbers – it improves the structure of the heart which in turn improves overall cardiac function,” said Bisognano.

CVRx Inc. funded the pivotal trial and the sub-analysis, which was also presented this week at the Scientific Sessions. In addition to Bisognano, Karl Illig, M.D., Jeremy Taylor, M.D., and James Sloand, M.D., from the Medical Center contributed to the research. Other collaborators include George Bakris, M.D., University of Chicago, Mitra Nadim, M.D., and Michael Fong, M.D., University of Southern California, Luis Sanchez, M.D., Washington University and Domenic Sica, M.D., Virginia Commonwealth University.

For Media Inquiries:
Emily Boynton
585-273-1757
Email Emily Boynton

Emily Boynton | EurekAlert!
Further information:
http://www.urmc.rochester.edu

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>